Arizona Has 30,000 Active Meth Cases and No Plan to Pay for the Only Proven Treatment
Five states have secured Medicaid waivers to fund contingency management for stimulant use disorder. Arizona, with the second-highest meth caseload in its public treatment system, is not one of them.
The Arizona Annual Substance Use Treatment Report filed with Governor Katie Hobbs in April 2026 is a document that the state produces and very few people read. It contains a number that everyone in Arizona’s behavioral health system should know: 29,707. That’s the total active methamphetamine and stimulant use disorder cases served through AHCCCS-funded treatment programs in state fiscal year 2025.
Meth is the second-most-common primary substance in Arizona’s public treatment population — behind only alcohol. It represents one of the largest treatment burdens the state carries, across 29 AHCCCS regional behavioral health authorities and every county in the state.
For none of these 29,707 people is Medicaid currently paying for contingency management — the one behavioral intervention with the clearest evidence base for stimulant use disorder.
That is not because CM has been tried and failed in Arizona. It is because Arizona has not filed the Section 1115 Medicaid waiver that would allow AHCCCS to reimburse it. The waiver pathway exists. The federal government has approved it in five states so far — California, Delaware, Hawaii, Montana, and Washington — with incentive structures ranging from $596 to $1,092 per enrolled patient. SAMHSA raised the allowable incentive cap from $75 to $750 per year in January 2025, removing the single biggest federal obstacle to CM expansion. The regulatory door is open.
Arizona hasn’t walked through it.
To be fair: Section 1115 waivers require state-level investment and administrative bandwidth. Arizona’s behavioral health system absorbed significant disruption through multiple rounds of SAMHSA grant uncertainty in 2026. The AHCCCS office is not a monolith, and waiver applications take time to prepare, negotiate, and approve. None of that is an excuse — it is context.
The context that matters more is Arizona’s opioid settlement funds. Arizona received more than $1.2 billion in settlement money from opioid manufacturers and distributors, legally earmarked for substance use disorder programs. One of the highest-evidence uses of that money would be funding a CM infrastructure while the Medicaid waiver is pending. Settlement funds, unlike Medicaid, don’t require the federal waiver dance.
Five states have figured out how to pay for contingency management through Medicaid. Arizona has 30,000 reasons to become the sixth.
Follow Rize’s Arizona Watch coverage for AHCCCS and state policy developments. Find treatment programs in Arizona at rizerecovery.com/find-help.
Sources Cited
- 01.A
- 02.B
- 03.BFederal Government Lifts Key Barrier to Stimulant Addiction CarePew Charitable Trusts
Filed Under
policytreatmentArizonaMethamphetamineContingency Management
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Overdose Deaths Fell Nationwide in 2025. Arizona Went the Other Way.
Overdose deaths fell about 14% nationally in 2025 but rose roughly 18% in Arizona, with fentanyl, methamphetamine and cocaine all up. What that means for naloxone, intake and settlement spending.
Arizona WatchArizona's September Naloxone Shipments Help, But They're Sized for a Crisis That's Shrinking Everywhere Except Here
Arizona is receiving 6,599 units of naloxone from Hikma and the first installment of a 33,714-unit Amneal shipment this September, under national opioid settlement deals. It's not enough given the state's rising overdose death toll.
Arizona WatchArizona Quietly Stopped Fighting Fentanyl. It's Chasing Landscapers Instead.
CBP data shows Arizona drug seizures collapsed from 27,000 to about 10,000 in three years. A DHS watchdog says it's because ICE redirected fentanyl investigators to immigration sweeps. Arizona's AG calls it a betrayal.